How big is Y-mAbs Therapeutics, Inc.?

As of Jun 18, Y-mAbs Therapeutics, Inc. has a market capitalization of 217.42 million and reported net sales of 88.66 million, with a net profit loss of 28.24 million. Shareholder's funds are at 92.00 million, and total assets are 119.90 million.

As of Jun 18, Y-mAbs Therapeutics, Inc. has a market capitalization of 217.42 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 88.66 million for the latest four quarters. During the same period, it experienced a net profit loss of 28.24 million.<BR><BR>As of Dec 24, the company's shareholder's funds stood at 92.00 million, while total assets were reported at 119.90 million.

What does Y-mAbs Therapeutics, Inc. do?

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies, with a market cap of $217.42 million and recent net sales of $21 million. The company reported a net loss of $5 million for the quarter ending March 2025.

Overview: <BR>Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 21 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 217.42 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.67 <BR>Return on Equity: -31.56% <BR>Price to Book: 2.43<BR><BR>Contact Details: <BR>Address: 750 3rd Ave Fl 9, NEW YORK NY: 10017-2718 <BR>Tel: 1 212 8479841 <BR>Fax: 1 302 6555049 <BR>Website: https://www.ymabs.com/

Should I buy, sell or hold Y-mAbs Therapeutics, Inc.?

Who are in the management team of Y-mAbs Therapeutics, Inc.?

As of March 2022, the management team of Y-mAbs Therapeutics, Inc. includes Mr. Thomas Gad (Chairman, President, Founder), Dr. Claus Moller-San Pedro (CEO), and Mr. Bo Kruse (CFO). The Board of Directors also features independent members such as Dr. Gerard Ber and Mr. David Gill.

As of March 2022, the management team of Y-mAbs Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Thomas Gad: Chairman of the Board, President, Founder, Head of Business Development and Strategy<BR>- Dr. Claus Moller-San Pedro: Chief Executive Officer, Director<BR>- Mr. Bo Kruse: Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director<BR><BR>Additionally, the Board of Directors includes several independent directors: <BR>- Dr. Gerard Ber<BR>- Mr. David Gill<BR>- Dr. James Healy<BR>- Dr. Ashutosh Tyagi<BR>- Mr. Johan Wedell-Wedellsborg<BR><BR>This structure highlights the leadership and governance of the company.

Is Y-mAbs Therapeutics, Inc. overvalued or undervalued?

As of February 25, 2021, Y-mAbs Therapeutics, Inc. is considered a risky investment due to its overvaluation, negative financial metrics, and significant underperformance compared to industry peers and the S&P 500.

As of 25 February 2021, the valuation grade for Y-mAbs Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its current financial metrics, including a Price to Book Value of 2.67 and an EV to Sales ratio of 2.02, which suggest that the stock is trading at a premium compared to its underlying assets and sales performance. Additionally, the company has a negative ROCE of -104.17% and a negative ROE of -31.56%, highlighting its struggles in generating returns for shareholders.<BR><BR>In comparison to its peers, Y-mAbs has a P/E ratio of -17.56, which is significantly worse than Lexicon Pharmaceuticals, Inc. at -3.53 and scPharmaceuticals, Inc. at -4.39, indicating that it is underperforming relative to its industry counterparts. Furthermore, the company's stock has underperformed against the S&P 500 over various periods, with a one-year return of -39.83% compared to the index's gain of 17.14%. This performance reinforces the notion that Y-mAbs is currently overvalued in the market.

Is Y-mAbs Therapeutics, Inc. technically bullish or bearish?

As of September 11, 2025, Y-mAbs Therapeutics, Inc. shows a bullish technical trend, supported by weekly indicators, despite mixed signals in longer-term metrics and underperformance compared to the S&P 500.

As of 11 September 2025, the technical trend for Y-mAbs Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a mildly bearish signal on the monthly timeframe. The KST is bullish on the weekly but bearish on the monthly, while the OBV is bullish across both timeframes. <BR><BR>In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a 1-year return of -39.83% versus the S&P's 17.14%, and a 5-year return of -79.18% compared to the S&P's 96.61%. Overall, the current technical stance is bullish, albeit with some mixed signals in the longer-term indicators.